Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Healthtrust
Cantor Fitzgerald
US Department of Justice
Moodys
UBS
QuintilesIMS
Teva
Express Scripts
Dow

Generated: January 19, 2018

DrugPatentWatch Database Preview

LASTACAFT Drug Profile

« Back to Dashboard

When do Lastacaft patents expire, and what generic alternatives are available?

Lastacaft is a drug marketed by Allergan and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has forty patent family members in twenty-eight countries.

The generic ingredient in LASTACAFT is alcaftadine. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the alcaftadine profile page.
Summary for LASTACAFT
International Patents:40
US Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: 3
Bulk Api Vendors: 33
Clinical Trials: 5
Patent Applications: 35
Drug Prices:see details
DailyMed Link:LASTACAFT at DailyMed
Drug patent expirations by year for LASTACAFT
Pharmacology for LASTACAFT

US Patents and Regulatory Information for LASTACAFT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan LASTACAFT alcaftadine SOLUTION/DROPS;OPHTHALMIC 022134-001 Jul 28, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for LASTACAFT
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Ophthalmic Solution 0.25% ➤ Subscribe 7/30/2014

International Patents for LASTACAFT

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
US Department of Justice
US Army
Moodys
Covington
Deloitte
Fuji
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot